These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
    Author: Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC.
    Journal: Cancer Treat Rep; 1985; 69(7-8):885-6. PubMed ID: 4016795.
    Abstract:
    Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m2 daily for 5 days. A 21% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 X 10(3)/ml and the median platelet count nadir was 184 X 10(3)/ml.
    [Abstract] [Full Text] [Related] [New Search]